AnaptysBio (ANAB) Receives Consensus Recommendation of “Buy” from Brokerages

AnaptysBio (NASDAQ:ANAB) has earned an average rating of “Buy” from the ten ratings firms that are presently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $138.63.

Several equities analysts recently issued reports on the stock. Credit Suisse Group set a $135.00 price objective on shares of AnaptysBio and gave the company an “outperform” rating in a report on Tuesday, January 23rd. Wedbush reissued an “outperform” rating and set a $151.00 price objective on shares of AnaptysBio in a report on Tuesday, March 27th. Royal Bank of Canada lifted their price objective on shares of AnaptysBio to $108.00 and gave the company an “outperform” rating in a report on Monday, December 18th. JMP Securities set a $180.00 price objective on shares of AnaptysBio and gave the company a “buy” rating in a report on Tuesday, March 27th. Finally, Jefferies Group lifted their price objective on shares of AnaptysBio from $6.59 to $145.00 and gave the company a “buy” rating in a report on Monday, February 19th.

How to Become a New Pot Stock Millionaire

A number of hedge funds have recently modified their holdings of the stock. New York State Common Retirement Fund grew its holdings in AnaptysBio by 21.4% in the third quarter. New York State Common Retirement Fund now owns 8,500 shares of the biotechnology company’s stock worth $297,000 after purchasing an additional 1,500 shares during the last quarter. Legal & General Group Plc grew its holdings in AnaptysBio by 160.8% in the third quarter. Legal & General Group Plc now owns 3,164 shares of the biotechnology company’s stock worth $110,000 after purchasing an additional 1,951 shares during the last quarter. Two Sigma Securities LLC purchased a new position in AnaptysBio in the fourth quarter worth $212,000. Amalgamated Bank purchased a new position in AnaptysBio in the fourth quarter worth $244,000. Finally, Raymond James Financial Services Advisors Inc. purchased a new position in AnaptysBio in the fourth quarter worth $252,000. 99.25% of the stock is currently owned by institutional investors.

Shares of AnaptysBio stock traded down $0.71 on Wednesday, hitting $87.49. 369,413 shares of the company traded hands, compared to its average volume of 380,303. The company has a debt-to-equity ratio of 0.02, a quick ratio of 17.93 and a current ratio of 17.93. AnaptysBio has a 52 week low of $18.15 and a 52 week high of $134.00. The company has a market capitalization of $2,100.03, a PE ratio of -58.03 and a beta of 3.27.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Monday, March 5th. The biotechnology company reported ($0.30) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.12. The company had revenue of $3.00 million for the quarter, compared to the consensus estimate of $0.89 million. The firm’s revenue was up 9.1% compared to the same quarter last year. analysts forecast that AnaptysBio will post -2.3 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “AnaptysBio (ANAB) Receives Consensus Recommendation of “Buy” from Brokerages” was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.chaffeybreeze.com/2018/04/16/anaptysbio-anab-receives-consensus-recommendation-of-buy-from-brokerages.html.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply